News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,350 Results
Type
Article (1589)
Company Profile (4)
Press Release (7757)
Section
Business (4072)
Career Advice (10)
Deals (538)
Drug Delivery (12)
Drug Development (1728)
Employer Resources (5)
FDA (312)
Job Trends (307)
News (6124)
Policy (556)
Tag
2027 BioCapital Standard (1)
Academia (22)
Accelerated approval (4)
ADA (1)
Adcomms (5)
Allergies (2)
Alliances (1028)
ALS (3)
Alzheimer's disease (22)
Antibody-drug conjugate (ADC) (26)
Approvals (293)
Artificial intelligence (17)
ASCO (3)
Autoimmune disease (16)
Bankruptcy (5)
Belgium (1)
Best Places to Work (153)
BIO (1)
BIOSECURE Act (1)
BioSpace Insights (5)
Biotechnology (1)
Breast cancer (4)
Cancer (136)
Cardiovascular disease (19)
Career advice (12)
CAR-T (2)
CDC (11)
CDMO (12)
Cell therapy (12)
Clinical research (1464)
Collaboration (68)
Company closure (3)
Compensation (6)
Complete response letters (5)
COVID-19 (120)
CRISPR (3)
C-suite (67)
Cystic fibrosis (1)
Data (99)
Denatured (3)
Depression (2)
Dermatology (3)
Diabetes (2)
Diagnostics (28)
Digital health (2)
Diversity, equity & inclusion (2)
Drug discovery (7)
Drug pricing (14)
Duchenne muscular dystrophy (6)
Earnings (1108)
Editorial (9)
Employer branding (2)
Employer resources (5)
Events (787)
Executive appointments (45)
FDA (348)
Frontotemporal dementia (3)
Funding (34)
Gene editing (5)
Generative AI (1)
Gene therapy (11)
GLP-1 (20)
Government (95)
Guidances (2)
Healthcare (197)
Hematology (1)
HIV (25)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (35)
Immuno-oncology (5)
Indications (7)
Infectious disease (193)
Inflammatory bowel disease (2)
Inflation Reduction Act (2)
Influenza (4)
Intellectual property (4)
IPO (133)
IRA (3)
Job creations (148)
Job search strategy (9)
JPM (7)
Kidney disease (5)
Labor market (7)
Layoffs (34)
Leadership (3)
Legal (152)
Licensing (5)
Liver cancer (2)
Longevity (1)
Lung cancer (24)
Lung diease (2)
Lymphoma (3)
Machine learning (1)
Management (2)
Manufacturing (25)
MASH (9)
Medical device (16)
Medtech (17)
Mergers & acquisitions (402)
Metabolic disorders (30)
mRNA (19)
Multiple sclerosis (1)
Neurodegenerative disease (22)
Neuropsychiatric disorders (4)
Neuroscience (53)
Neurotech (1)
NextGen: Class of 2026 (77)
Non-profit (31)
Now hiring (1)
Obesity (19)
Opinion (14)
Ovarian cancer (10)
Pain (1)
Pancreatic cancer (13)
Parkinson's disease (2)
Partnered (1)
Patents (13)
Patient recruitment (6)
Patient selection (1)
People (1437)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase 1 (373)
Phase 2 (585)
Phase 3 (598)
Pipeline (202)
Policy (29)
Postmarket research (98)
Preclinical (114)
Prostate cancer (6)
Psychedelics (3)
Radiopharmaceuticals (4)
Rare diseases (39)
Real estate (76)
Recruiting (1)
Regulatory (454)
Reports (2)
Research institute (30)
Resumes & cover letters (1)
RNA editing (2)
RSV (32)
Schizophrenia (1)
Series A (6)
Series B (2)
Sickle cell disease (4)
Special edition (6)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (109)
Stomach cancer (5)
Supply chain (3)
Tariffs (6)
The Weekly (17)
Vaccines (126)
Venture capital (15)
Weight loss (12)
Date
Today (1)
Last 7 days (14)
Last 30 days (51)
Last 365 days (481)
2026 (398)
2025 (462)
2024 (494)
2023 (532)
2022 (723)
2021 (606)
2020 (516)
2019 (408)
2018 (330)
2017 (398)
2016 (429)
2015 (658)
2014 (461)
2013 (384)
2012 (337)
2011 (394)
2010 (385)
Location
Africa (36)
Arizona (1)
Asia (609)
Australia (175)
California (161)
Canada (61)
China (43)
Colorado (2)
Connecticut (2)
Delaware (2)
Europe (3246)
Florida (17)
Georgia (9)
Illinois (36)
India (1)
Indiana (3)
Japan (3)
Maryland (9)
Massachusetts (164)
Michigan (1)
Nevada (1)
New Hampshire (5)
New Jersey (64)
New York (19)
North Carolina (13)
Northern California (80)
Oklahoma (1)
Pennsylvania (39)
Puerto Rico (1)
South America (22)
Southern California (60)
Texas (55)
United States (561)
Utah (4)
Virginia (5)
Washington D.C. (3)
Washington State (10)
Wisconsin (1)
9,350 Results for "gsk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
GSK vaccine sales miss expectations amid falling demand from adults
With pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.
October 28, 2026
·
2 min read
·
Nick Paul Taylor
Layoffs
GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum
The layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.
October 14, 2026
·
1 min read
·
Gabrielle Masson
Manufacturing
GSK pledges $800M to add biologics production capabilities in Pennsylvania
Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial supply. The investment will create more than 300 new jobs over the next five years, Pennsylvania state officials said.
October 12, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer assets in late-stage development.
July 23, 2026
·
2 min read
·
Tristan Manalac
Layoffs
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
GSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.
September 15, 2026
·
2 min read
·
Tristan Manalac
Vaccines
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
September 1, 2026
·
1 min read
·
Heather McKenzie
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.
September 15, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
September 30, 2026
·
4 min read
Earnings
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the first quarter, emerging as the pharma’s top-selling product.
April 29, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
GSK abandons Alector after back-to-back neuro stumbles
GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit.
July 9, 2026
·
2 min read
·
Tristan Manalac
1 of 935
Next
